Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant

Ying Taur(Memorial Sloan Kettering Cancer Center), Katharine Z. Coyte(Boston Children's Hospital), Jonas Schlüter(Memorial Sloan Kettering Cancer Center), Elizabeth Robilotti(Memorial Sloan Kettering Cancer Center), Cesar J. Figueroa(Memorial Sloan Kettering Cancer Center), Mergim Gjonbalaj(Memorial Sloan Kettering Cancer Center), Eric R. Littmann(Memorial Sloan Kettering Cancer Center), Lilan Ling(Memorial Sloan Kettering Cancer Center), Liza Miller(Memorial Sloan Kettering Cancer Center), Yangtsho Gyaltshen(Memorial Sloan Kettering Cancer Center), Emily Fontana(Memorial Sloan Kettering Cancer Center), Sejal Morjaria(Memorial Sloan Kettering Cancer Center), Boglarka Gyurkocza(Memorial Sloan Kettering Cancer Center), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Hugo Castro‐Malaspina(Memorial Sloan Kettering Cancer Center), Roni Tamari(Memorial Sloan Kettering Cancer Center), Doris M. Ponce(Memorial Sloan Kettering Cancer Center), Guenther Koehne(Memorial Sloan Kettering Cancer Center), Juliet Barker(Memorial Sloan Kettering Cancer Center), Ann A. Jakubowski(Memorial Sloan Kettering Cancer Center), Esperanza B. Papadopoulos(Memorial Sloan Kettering Cancer Center), Parastoo B. Dahi(Memorial Sloan Kettering Cancer Center), Craig S. Sauter(Memorial Sloan Kettering Cancer Center), Brian C. Shaffer(Memorial Sloan Kettering Cancer Center), James W. Young(Memorial Sloan Kettering Cancer Center), Jonathan U. Peled(Memorial Sloan Kettering Cancer Center), Richard Meagher(Memorial Sloan Kettering Cancer Center), Robert R. Jenq(The University of Texas MD Anderson Cancer Center), Marcel R.M. van den Brink(Memorial Sloan Kettering Cancer Center), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Eric G. Pamer(Memorial Sloan Kettering Cancer Center), João B. Xavier(Memorial Sloan Kettering Cancer Center)
Science Translational Medicine
September 26, 2018
Cited by 369

Abstract

Antibiotic treatment can deplete the commensal bacteria of a patient's gut microbiota and, paradoxically, increase their risk of subsequent infections. In allogeneic hematopoietic stem cell transplantation (allo-HSCT), antibiotic administration is essential for optimal clinical outcomes but significantly disrupts intestinal microbiota diversity, leading to loss of many beneficial microbes. Although gut microbiota diversity loss during allo-HSCT is associated with increased mortality, approaches to reestablish depleted commensal bacteria have yet to be developed. We have initiated a randomized, controlled clinical trial of autologous fecal microbiota transplantation (auto-FMT) versus no intervention and have analyzed the intestinal microbiota profiles of 25 allo-HSCT patients (14 who received auto-FMT treatment and 11 control patients who did not). Changes in gut microbiota diversity and composition revealed that the auto-FMT intervention boosted microbial diversity and reestablished the intestinal microbiota composition that the patient had before antibiotic treatment and allo-HSCT. These results demonstrate the potential for fecal sample banking and posttreatment remediation of a patient's gut microbiota after microbiota-depleting antibiotic treatment during allo-HSCT.


Related Papers

No related papers found

Powered by citation graph analysis